Literature DB >> 19682090

Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.

Ritsuko Shimizu1, Eri Kobayashi, James Douglas Engel, Masayuki Yamamoto.   

Abstract

Two GATA1-related leukemias have been described: one is an erythroleukemia that develops in mice as a consequence of diminished expression of wild-type GATA1, whereas the other is an acute megakaryoblastic leukemia (AMKL) that arises in Down syndrome children as a consequence of somatic N-terminal truncation (DeltaNT) of GATA1. We discovered that mice expressing the shortened GATA1 protein (DeltaNTR mice) phenocopies the human transient myeloproliferative disorder (TMD) that precedes AMKL in Down syndrome children. In perinatal livers of the DeltaNTR mutant mice, immature megakaryocytes accumulate massively, and this fraction contains cells that form hyperproliferative megakaryocytic colonies. Furthermore, showing good agreement with the clinical course of TMD in humans, DeltaNTR mutant mice undergo spontaneous resolution from the massive megakaryocyte accumulation concomitant with the switch of hematopoietic microenvironment from liver to bone marrow/spleen. These results thus demonstrate that expression of the GATA1/Gata1 N-terminal deletion mutant per se induces hyperproliferative fetal megakaryopoiesis. This mouse model serves as an important means to clarify how impaired GATA1 function contributes to the multi-step leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682090     DOI: 10.1111/j.1365-2443.2009.01338.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  9 in total

Review 1.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 2.  Myeloid leukemia in Down syndrome.

Authors:  Irum Khan; Sébastien Malinge; John Crispino
Journal:  Crit Rev Oncog       Date:  2011

3.  N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.

Authors:  Hiroshi Kaneko; Eri Kobayashi; Masayuki Yamamoto; Ritsuko Shimizu
Journal:  J Biol Chem       Date:  2012-05-02       Impact factor: 5.157

Review 4.  The biology of pediatric acute megakaryoblastic leukemia.

Authors:  Tanja A Gruber; James R Downing
Journal:  Blood       Date:  2015-07-17       Impact factor: 22.113

5.  GATA Transcription Factors and Cancer.

Authors:  Rena Zheng; Gerd A Blobel
Journal:  Genes Cancer       Date:  2010-12

Review 6.  GATA1 Activity Governed by Configurations of cis-Acting Elements.

Authors:  Atsushi Hasegawa; Ritsuko Shimizu
Journal:  Front Oncol       Date:  2017-01-09       Impact factor: 6.244

Review 7.  Development of platelet replacement therapy using human induced pluripotent stem cells.

Authors:  Sou Nakamura; Naoshi Sugimoto; Koji Eto
Journal:  Dev Growth Differ       Date:  2021-03-04       Impact factor: 2.053

Review 8.  Advances in molecular characterization of myeloid proliferations associated with Down syndrome.

Authors:  Jixia Li; Maggie L Kalev-Zylinska
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

9.  GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.

Authors:  Naery Yang; Sholhui Park; Min Sun Cho; Miae Lee; Ki Sook Hong; Yeung Chul Mun; Chu Myong Seong; Hee Jin Huh; Jungwon Huh
Journal:  Ann Lab Med       Date:  2018-07       Impact factor: 3.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.